Improvement of quality of life by means of antitachy pacing

From PainFREE to the ADVANCE-D trial

Maurizio Lunati, Pascal Defaye, Johann Mermi, Arcadi Garcia-Alberola, José L. Merino, Angel Arenal, Riccardo Cappato, Xavier Navarro, Micaela Passardi, Massimo Santini

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachyarrhythmias with shocks (painful) or antitachycardia pacing (painless). According to the results of the Pacing Fast VT Reduces Shock ThErapies Trials, antitachycardia pacing (ATP) can avoid painful shocks and also increase device longevity. The purpose of the ADVANCE-D (Atp DeliVery for PAiNless ICD ThErapy) study is to determine the most appropriate ventricular tachycardia (VT) therapy, so as to optimize painless therapy for life-threatening arrhythmias. Methods and Results: The ADVANCE-D is a prospective, multicenter, parallel, two-arm randomized study designed to evaluate the efficacy of two different sequences of ATP therapies (burst 15 pulses, 88%, vs burst 8 pulses, 88%), during an episode of spontaneous arrhythmia classified as fast VT (FVT) in patients with a Class I or IIA indication for ICD implantation (single and dual chamber devices). The primary endpoint is to compare the efficacy of two ATP therapies for FVT episodes. The study will enroll a minimum of 900 patients within 2 years, followed-up for 12 months. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE-D trial is the first large randomized clinical investigation aimed to evaluate optimal programming and efficacy of ATP.

Original languageEnglish
JournalPACE - Pacing and Clinical Electrophysiology
Volume29
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Dec 2006

Fingerprint

Quality of Life
Implantable Defibrillators
Ventricular Tachycardia
Cardiac Arrhythmias
Shock
Convulsive Therapy
Therapeutics
Equipment and Supplies
Tachycardia

Keywords

  • Antitachycardia pacing
  • Implantable cardioverter/defibrillator
  • Ventricular tachyarrhythmias

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Improvement of quality of life by means of antitachy pacing : From PainFREE to the ADVANCE-D trial. / Lunati, Maurizio; Defaye, Pascal; Mermi, Johann; Garcia-Alberola, Arcadi; Merino, José L.; Arenal, Angel; Cappato, Riccardo; Navarro, Xavier; Passardi, Micaela; Santini, Massimo.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 29, No. SUPPL. 2, 12.2006.

Research output: Contribution to journalArticle

Lunati, M, Defaye, P, Mermi, J, Garcia-Alberola, A, Merino, JL, Arenal, A, Cappato, R, Navarro, X, Passardi, M & Santini, M 2006, 'Improvement of quality of life by means of antitachy pacing: From PainFREE to the ADVANCE-D trial', PACE - Pacing and Clinical Electrophysiology, vol. 29, no. SUPPL. 2. https://doi.org/10.1111/j.1540-8159.2006.00488.x
Lunati, Maurizio ; Defaye, Pascal ; Mermi, Johann ; Garcia-Alberola, Arcadi ; Merino, José L. ; Arenal, Angel ; Cappato, Riccardo ; Navarro, Xavier ; Passardi, Micaela ; Santini, Massimo. / Improvement of quality of life by means of antitachy pacing : From PainFREE to the ADVANCE-D trial. In: PACE - Pacing and Clinical Electrophysiology. 2006 ; Vol. 29, No. SUPPL. 2.
@article{67ac434c693a42769ee9105af05acf58,
title = "Improvement of quality of life by means of antitachy pacing: From PainFREE to the ADVANCE-D trial",
abstract = "Background: Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachyarrhythmias with shocks (painful) or antitachycardia pacing (painless). According to the results of the Pacing Fast VT Reduces Shock ThErapies Trials, antitachycardia pacing (ATP) can avoid painful shocks and also increase device longevity. The purpose of the ADVANCE-D (Atp DeliVery for PAiNless ICD ThErapy) study is to determine the most appropriate ventricular tachycardia (VT) therapy, so as to optimize painless therapy for life-threatening arrhythmias. Methods and Results: The ADVANCE-D is a prospective, multicenter, parallel, two-arm randomized study designed to evaluate the efficacy of two different sequences of ATP therapies (burst 15 pulses, 88{\%}, vs burst 8 pulses, 88{\%}), during an episode of spontaneous arrhythmia classified as fast VT (FVT) in patients with a Class I or IIA indication for ICD implantation (single and dual chamber devices). The primary endpoint is to compare the efficacy of two ATP therapies for FVT episodes. The study will enroll a minimum of 900 patients within 2 years, followed-up for 12 months. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE-D trial is the first large randomized clinical investigation aimed to evaluate optimal programming and efficacy of ATP.",
keywords = "Antitachycardia pacing, Implantable cardioverter/defibrillator, Ventricular tachyarrhythmias",
author = "Maurizio Lunati and Pascal Defaye and Johann Mermi and Arcadi Garcia-Alberola and Merino, {Jos{\'e} L.} and Angel Arenal and Riccardo Cappato and Xavier Navarro and Micaela Passardi and Massimo Santini",
year = "2006",
month = "12",
doi = "10.1111/j.1540-8159.2006.00488.x",
language = "English",
volume = "29",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Improvement of quality of life by means of antitachy pacing

T2 - From PainFREE to the ADVANCE-D trial

AU - Lunati, Maurizio

AU - Defaye, Pascal

AU - Mermi, Johann

AU - Garcia-Alberola, Arcadi

AU - Merino, José L.

AU - Arenal, Angel

AU - Cappato, Riccardo

AU - Navarro, Xavier

AU - Passardi, Micaela

AU - Santini, Massimo

PY - 2006/12

Y1 - 2006/12

N2 - Background: Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachyarrhythmias with shocks (painful) or antitachycardia pacing (painless). According to the results of the Pacing Fast VT Reduces Shock ThErapies Trials, antitachycardia pacing (ATP) can avoid painful shocks and also increase device longevity. The purpose of the ADVANCE-D (Atp DeliVery for PAiNless ICD ThErapy) study is to determine the most appropriate ventricular tachycardia (VT) therapy, so as to optimize painless therapy for life-threatening arrhythmias. Methods and Results: The ADVANCE-D is a prospective, multicenter, parallel, two-arm randomized study designed to evaluate the efficacy of two different sequences of ATP therapies (burst 15 pulses, 88%, vs burst 8 pulses, 88%), during an episode of spontaneous arrhythmia classified as fast VT (FVT) in patients with a Class I or IIA indication for ICD implantation (single and dual chamber devices). The primary endpoint is to compare the efficacy of two ATP therapies for FVT episodes. The study will enroll a minimum of 900 patients within 2 years, followed-up for 12 months. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE-D trial is the first large randomized clinical investigation aimed to evaluate optimal programming and efficacy of ATP.

AB - Background: Implantable cardioverter-defibrillators (ICD) can terminate ventricular tachyarrhythmias with shocks (painful) or antitachycardia pacing (painless). According to the results of the Pacing Fast VT Reduces Shock ThErapies Trials, antitachycardia pacing (ATP) can avoid painful shocks and also increase device longevity. The purpose of the ADVANCE-D (Atp DeliVery for PAiNless ICD ThErapy) study is to determine the most appropriate ventricular tachycardia (VT) therapy, so as to optimize painless therapy for life-threatening arrhythmias. Methods and Results: The ADVANCE-D is a prospective, multicenter, parallel, two-arm randomized study designed to evaluate the efficacy of two different sequences of ATP therapies (burst 15 pulses, 88%, vs burst 8 pulses, 88%), during an episode of spontaneous arrhythmia classified as fast VT (FVT) in patients with a Class I or IIA indication for ICD implantation (single and dual chamber devices). The primary endpoint is to compare the efficacy of two ATP therapies for FVT episodes. The study will enroll a minimum of 900 patients within 2 years, followed-up for 12 months. The investigation is expected to be completed in 2007. Conclusions: The ADVANCE-D trial is the first large randomized clinical investigation aimed to evaluate optimal programming and efficacy of ATP.

KW - Antitachycardia pacing

KW - Implantable cardioverter/defibrillator

KW - Ventricular tachyarrhythmias

UR - http://www.scopus.com/inward/record.url?scp=33751380058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751380058&partnerID=8YFLogxK

U2 - 10.1111/j.1540-8159.2006.00488.x

DO - 10.1111/j.1540-8159.2006.00488.x

M3 - Article

VL - 29

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - SUPPL. 2

ER -